Congratulations to the regulatory, quality, SD&I, R&D, PMO, clinical affairs, and commercial teams and many more at DiaSorin and Luminex
The active form of the drug has a central nervous system stimulating activity by the primary inhibition of DAT, NET, trace amine-associated receptor 1 (TAAR1) and vesicular monoamine transporter 2 (SLC18A2), among other targets, therefore regulating the reuptake and release of catecholamines (primarily NE and DA) on the synaptic cleft
This method follows the approach of Brenner & Schedl (2016) [73] with following differences
UTIs are common in the general population, especially among women, and coincidental timing with tirzepatide use can create a false association
doi: 10.1016/j.pharep.2018.12.006